|4Mar 28, 6:03 PM ET

Cannon Kara 4

4 · ENZO BIOCHEM INC · Filed Mar 28, 2022

Insider Transaction Report

Form 4
Period: 2022-03-24
Cannon Kara
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (to acquire Common Stock)

    2022-03-24+87,50087,500 total
    Exercise: $2.98From: 2023-03-24Exp: 2027-03-24Common Stock (87,500 underlying)
Holdings
  • Stock Option (to acquire Common Stock)

    Exercise: $2.20From: 2021-02-24Exp: 2025-02-24Common Stock (55,400 underlying)
    55,400
  • Stock Option (to acquire Common Stock)

    Exercise: $2.80From: 2020-01-03Exp: 2024-01-03Common Stock (52,000 underlying)
    52,000
  • Stock Option (to acquire Common Stock)

    Exercise: $3.36From: 2023-02-11Exp: 2027-02-11Common Stock (87,500 underlying)
    87,500
  • Common Stock, $0.01 Par Value

    (indirect: By 401(k))
    22,614
  • Stock Option (to acquire Common Stock)

    Exercise: $2.63From: 2022-01-11Exp: 2026-01-11Common Stock (55,400 underlying)
    55,400
  • Stock Option (to acquire Common Stock)

    Exercise: $4.42From: 2019-07-31Exp: 2023-07-30Common Stock (35,000 underlying)
    35,000
Footnotes (1)
  • [F1]The stock options have a five-year term and will vest in three equal installments, one on the first anniversary of the grant date, the second on the second anniversary of the grant date and the third on the third anniversary of the grant date.

Documents

1 file
  • 4
    ownership.xmlPrimary